Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US ... t include any data which shows use of Relvar Ellipta can help reduce more clear-cut clinical ...

Do not initiate in rapidly or acutely deteriorating COPD or asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist ...

Its new use is based on an analysis of the phase 3 IMPACT study, which showed Trelegy was better than GSK’s already approved combinations Relvar/Breo Ellipta and Anoro Ellipta. Trelegy is also ...